New research unveils on medication management for diabetes patients during Ramadan

The “Ertu Ramadan Study Dissemination Program” concluded recently with a significant milestone in diabetes research at Pan Pacific Sonargaon, Dhaka.

Organised by Synovia Pharma PLC, the event celebrated the publication of the Ertu Ramadan Study in Frontiers in Endocrinology (Impact Factor: 3.9), shedding light on the real-world effectiveness of Ertugliflozin in managing Type-2 diabetes mellitus (T2DM) during Ramadan fasting, according to a press  release.

The chief guest at the event was Dr AK Azad Khan, President of the Diabetic Association of Bangladesh (BADAS). M A Samad, CEO of the National Health Network (NHN), was present as a special guest.

Professor Dr Hafizur Rahman, Department of Endocrinology, United Hospital Ltd, and President of Bangladesh Endocrine Society, also presided over the programme.

The study was led by Prof Faruque Pathan, Director of Birdem Academy, and Dr Shahjada Selim, Associate Professor of Endocrinology at BSMMU, along with a team of renowned Endocrinologists from Bangladesh and the Bangladesh Endocrine Society.

In his address, Professor Faruque Pathan provided insights into the study's background and the role of SGLT2 inhibitors in Ramadan fasting, where Dr Shahjada Selim presented the study’s key findings, demonstrating the effectiveness and safety of Ertugliflozin in real-world settings.

The programme also featured an engaging expert panel discussion with investigators from prestigious institutions such as BIRDEM, BSMMU, Dhaka Medical College, and other leading medical centres. The session emphasised the study’s impact on clinical practice, aiming to enhance diabetes care strategies for fasting patients.